anti-d

PreclinicalSmall molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

anti-d is one of 4 small molecule programs targeting Dengue Fever. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dengue FeverCompleted

Dengue FeverPreclinical

Completed

Competition

Competitive Landscape

3 competitors in Dengue Fever

#DrugCompanyPhaseTrials

Tetravalent Dengue Vaccine (TDV)

Takeda

Phase 3

1 2

Relenza

GGlaxo Dba Glaxosmithkline

Phase 2

1 3

Butantan - DV

BButantan Institute

Phase 3

1 4

anti-d

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Completed·UUniversity of Aarhus·Phase 2·NCT00128882·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for anti-d. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-d compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-d. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

anti-d

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dengue Fever1 trial

Thrombocytopenia1 trial

Thrombocytopenic Purpura1 trial

References

Drug Info

Quick Facts

Related News